#USA #New York #Class Action #Revance Therapeutics #Settlement

Proposed Settlement Overview

Revance Therapeutics, Inc. has found itself at the center of a significant legal matter recently adjudicated by Monteverde & Associates PC and Kahn Swick & Foti, LLC. Following a merger with Crown Laboratories, Inc. in February 2025, a class action lawsuit has arisen on behalf of the shareholders impacted by this transaction. The recent announcement reveals a proposed settlement of $2.4 million intended for holders of Revance common stock, specifically geared towards those not eligible for compensation under the previous settlement reached in the ongoing legal proceedings.

The notice outlines critical eligibility criteria for class members, stating that affected shareholders must have been record holders of Revance common stock as of February 6, 2025. Additionally, the settlement targets those who exchanged their shares for $3.65 each during the merger process. This action has already captured the attention of many shareholders, who are now able to seek compensation despite initial barriers that left some individuals without recourse.

Details of the Settlement

As part of the recently proposed settlement, there are several important facets that affected individuals should be aware of:

• - Class Action Structure: The court will hold a hearing on December 17, 2026, at which time it will determine whether the class meets the necessary criteria to be certified as a non-opt-out class action. This is a crucial step that could ultimately provide shareholders with an equitable resolution.
• - Filing Requirements: Shareholders who believe they are entitled to compensation must submit a Proof of Claim and Release form by March 17, 2027. It's important for members of the class to act promptly to ensure they secure their share of the settlement funds. Individuals also have the right to appear and voice their opinions during the hearing.
• - Objection Process: For those who wish to voice objections to the terms of the proposed settlement or the allocation plan, the court has established a clear process. Interested parties must file their objections by December 3, 2026, ensuring they adhere to specified guidelines. Any objector may present evidence or arguments at the settlement hearing to support their case.
• - Legal Representation: The legal teams representing the plaintiffs, comprising Monteverde & Associates and Kahn Swick & Foti, are tasked with ensuring that the suit's objectives are well-represented. They will also be responsible for overseeing the administration of the settlement and addressing any questions shareholders might have during this process.

Conclusion

This proposed settlement marks a vital development for many Revance shareholders who have encountered challenges since the merger with Crown Laboratories. As the December 2026 hearing approaches, it becomes increasingly important for affected parties to stay informed and engaged in the proceedings. This case exemplifies the type of legal complexities that can arise following corporate mergers and acquisitions and underscores the importance of adequate legal representation for shareholders.

For further details or if you believe you qualify for the settlement, stakeholders are encouraged to reach out directly to the legal representatives overseeing the case. This pivotal hearing may lead to significant financial recourse for those involved.

Stay tuned for updates as this story develops.